Search results

1. Erasca dips on patient death

   … based on early data reported by Revolution at ESMO 2023 . Curiously, daraxonrasib is sometimes also … Venue Apr 2026  company presentation ESMO 2023 Apr 2026  company presentation ESMO 2023 Setting 2nd-line plus 2nd-line …

   
    

   Madeleine Armstrong
    
   - 04/30/2026 - 10:19

2. SGO 2026 – BioNTech’s Enhertu me-too comes up short

   … ph2 Destiny-PanTumor02 Venue SGO 2026 ESMO 2023 ORR 48% (46/96) 58% (23/40) … tested pts. Source: Society of Gynecologic Oncology 2026 & ESMO 2023. Conferences Trial …

   
    

   Madeleine Armstrong
    
   - 04/14/2026 - 14:07

3. ESMO 2025 preview – first clinical results

   … G12D asset HRS-4642, whose 6% ORR was a big letdown at ESMO 2023 . What stands out especially regarding the new …

   
    

   Jacob Plieth
    
   - 10/15/2025 - 09:57

4. Zelgen’s DLL3 trispecific goes pivotal

   … Harpoon) Ph1/2  data in 2nd-line solid tumours at ESMO 2023: ORR 35% across tumour types; ifinatamab-dxd combo …

   
    

   Madeleine Armstrong
    
   - 10/02/2025 - 14:19

5. HengRui presses on in HER3, despite Merck’s failure

   … go on so far. In a phase 1 solid tumour trial presented at ESMO 2023 ruza-can produced an ORR of 30% among 30 NSCLC …

   
    

   Madeleine Armstrong
    
   - 09/25/2025 - 12:14

6. DLL3 goes trispecific

   … Harpoon) Ph1/2 data in 2nd-line solid tumours at ESMO 2023: ORR 35% across tumour types; ifinatamab-dxd combo …

   
    

   Madeleine Armstrong
    
   - 09/29/2025 - 12:49

7. NextCure joins Merck in an ovarian target

   … Ph3 Rejoice-Ovarian01 completes Dec 2027; ph1 data at ESMO 2023: cORR 46% (23/50) in ovarian cancer* CUSP06 …

   
    

   Madeleine Armstrong
    
   - 06/19/2025 - 11:19

8. Lepu starts another pivotal conjugate trial

   … similar setting will feature in a late-breaking session. At ESMO 2023 the same phase 2 produced ORRs of 39% and 55% with …

   
    

   Madeleine Armstrong
    
   - 05/22/2025 - 13:39

9. Novartis gets a PSMAfore green flag at last

   … or a different androgen-receptor-targeting therapy. At ESMO 2023 it became apparent that, although the study had …   Final analysis 2nd interim analysis  (ESMO 2023) Crossover 60% 84% OS HR … 0.38-0.91 0.48-1.33 Source: company releases & ESMO 2023.   This was clearly enough for the FDA; the …

   
    

   Madeleine Armstrong
    
   - 04/01/2025 - 16:46

10. ELCC 2025 – BioNTech impresses in small-cell lung

    … 42% – lower than the 73% reported from the same study at ESMO 2023. Still, the result is in line with the 40% ORR …

    
     

    Madeleine Armstrong
     
    - 04/01/2025 - 16:09